Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.63 |
| ▸ | TUBB | P07437 | 1/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.63 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.63 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.63 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.61 |
| ▸ | HPGD | P15428 | 7/20 | 0.61 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Skimmianine SCHEMBL6933482 | 0.87 | ALDH1A1 (0.80) | POLBKDM4ETUBB4ATUBBTUBA3C | |
| SCHEMBL1408391 | 0.80 | POLB (1.00) | POLBKDM4EALDH1A1HPGDKMT2A | |
| Evolitrine SCHEMBL30105705 | 0.80 | KDM4E (0.67) | POLBKDM4ETUBB4ATUBBTUBA3C | |
| Confusameline SCHEMBL21784044 | 0.78 | KDM4E (0.65) | POLBKDM4ETUBB4ATUBBTUBA3C | |
| Confusameline SCHEMBL30525089 | 0.78 | KDM4E (0.65) | POLBKDM4ETUBB4ATUBBTUBA3C | |
| Kokusaginine SCHEMBL23870280 | 0.78 | KDM4E (1.00) | POLBKDM4ETUBB4ATUBBTUBA3C | |
| Kokusaginine SCHEMBL30609976 | 0.78 | KDM4E (1.00) | POLBKDM4ETUBB4ATUBBTUBA3C | |
| Gamma-Fagarine SCHEMBL29594141 | 0.76 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Gamma-Fagarine SCHEMBL679918 | 0.76 | KDM4E (1.00) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| Calycanthine SCHEMBL6410222 | 0.75 | KDM4E (0.39) | POLBKDM4ETUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010968-A | Furanoquinoline dictamnine derivative and preparation method and application thereof | 广东药科大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4714440-A2 | A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS | Kurek, Janusz (PL) | 2026-03-25 | — | — | EP | claimed |
| CN-114267421-B | Extraction process for optimizing three effective components of cortex dictamni by combining analytic hierarchy process with response surface method | 吉林化工学院 | 2025-05-23 | — | — | CN | claimed |
| CN-119925370-A | Application of dictamnine in preparation of osteosarcoma and osteosarcoma-induced osteolysis diseases | 广西医科大学 | 2025-05-06 | — | — | CN | claimed |
| CN-119241598-A | 8-Hydroxy dittany alkali iridium (III) complex and synthetic method and application thereof | 玉林师范学院 | 2025-01-03 | — | — | CN | claimed |
| CN-114891010-B | Method for extracting and purifying dictamnine compounds in cortex dictamni and application of method in resisting MRSA | 郑州大学 | 2024-11-08 | — | — | CN | claimed |
| CN-118671253-A | Establishment of HPLC fingerprint spectrum of crude alkaloid in radix zanthoxyli and anti-leukemia activity spectrum effect analysis method | 贵州省天然产物研究中心 | 2024-09-20 | — | — | CN | claimed |
| CN-118450720-A | Alkaloid modified perovskite photoactive layer, solar cell and preparation method | 武汉理工大学 | 2024-08-06 | — | — | CN | claimed |
| CN-118178302-A | Preparation method and application of medical hemorrhoid gel | 广东中科育华医学研究院 | 2024-06-14 | — | — | CN | claimed |
| CN-114133401-B | Preparation method of dictamnine monomer | 吉林化工学院 | 2024-05-31 | — | — | CN | claimed |
| CN-101805344-A | Purification method of monomeric compound in root bark of shaggy-fruited dittany | NANJING ZELANG MEDICAL TECH CO | 2010-08-18 | — | — | CN | claimed |
| EP-2200611-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen Idec MA, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| CN-101543546-A | Antioxidative substance and composition and use thereof | SHANGHAI AMBROSIA PHARMACEUTIC | 2009-09-30 | — | — | CN | claimed |
| WO-2009038684-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC. (US) | 2009-03-26 | — | — | WO | claimed |
| CN-101011406-A | Composition used as gynaecologic externally used agent | LIU XIAOJUN (CN) | 2007-08-08 | — | — | CN | claimed |
| WO-2005023280-A1 | ORAL TREATMENT FOR ANORECTAL CONDITIONS | VITAL PHARMACEUTICALS (SICHUAN) COMPANY LIMITED (CN) | 2005-03-17 | — | — | WO | claimed |
| US-20050053682-A1 | Oral treatment for anorectal conditions | VITAL PHARMACEUTICALS(SICHUAN) COMPANY LIMITED | 2005-03-10 | — | — | US | claimed |
| US-20040192579-A1 | Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases | GLOBAL CANCER STRATEGIES LTD. (CA) | 2004-09-30 | — | — | US | claimed |
| EP-1370274-A1 | COMPOSITIONS COMPRISING MATRINE AND DICTAMNINE FOR TREATING OR PREVENTING CANCER AND OTHER DISEASES | Global Cancer Strategies Ltd. (CA) | 2003-12-17 | — | — | EP | claimed |
| WO-2002072120-A1 | COMPOSITIONS COMPRISING MATRINE AND DICTAMNINE FOR TREATING OR PREVENTING CANCER AND OTHER DISEASES | GLOBAL CANCER STRATEGIES LTD. (CA) | 2002-09-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053682-A1 | Oral treatment for anorectal conditions | ALPI, OAT, SI | POLB 1841/4885KDM4E 4081/4885TUBB4A 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.